Trials / Completed
CompletedNCT06851325
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
Antiplatelets and Hemorrhagic MI
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,180 (actual)
- Sponsor
- Rohan Dharmakumar · Academic / Other
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- —
Summary
The MIRON-PLATELET study is a retrospective, observational multi-center analysis assessing the impact of different antiplatelet therapies on hemorrhagic myocardial infarction (HMI) incidence and outcomes in STEMI patients. Key endpoints include hemorrhagic transformation, MACE, bleeding complications, and 30-day mortality. Findings will offer insights into the safety and clinical implications of antiplatelet therapy in high-risk patients.
Conditions
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2025-01-30
- Completion
- 2025-02-11
- First posted
- 2025-02-28
- Last updated
- 2026-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06851325. Inclusion in this directory is not an endorsement.